Photobiomodulation for chemotherapy-induced peripheral neuropathy: symptomatic effectiveness in a real-world single-center cohort
In a real-world single-center cohort of patients with chronic chemotherapy-induced peripheral neuropathy, photobiomodulation treatment resulted in significant, durable symptomatic relief with no attributable toxicity, warranting further randomized confirmation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For many cancer patients, the battle against the disease does not end when the chemotherapy infusions stop. A common and often lingering side effect of these powerful drugs is a condition where the nerves in the hands and feet become damaged, leading to a persistent sensation of numbness, tingling, or burning pain. This condition, known as chemotherapy-induced peripheral neuropathy, can feel like wearing gloves or socks that are too tight, even when the skin is bare. It is a frequent reason why doctors must lower drug doses or stop treatment early, potentially jeopardizing the fight against the cancer itself. While some patients eventually recover, a significant number are left with chronic discomfort that current medicines struggle to relieve, leaving them searching for any form of lasting relief.
In a recent study conducted at a hospital in France, researchers explored a non-drug approach to help patients suffering from this specific type of nerve pain. They turned to a technique called photobiomodulation, which uses specific colors of light to interact with the body's cells. Think of this process as a gentle, targeted energy source that helps tired or injured cells repair themselves, rather than a beam that burns or cuts. The team treated a group of patients who had already developed this nerve damage and were struggling with symptoms that had not gone away on their own. By shining a combination of red and near-infrared light onto the painful hands and feet, they aimed to see if this simple, painless application could reduce the suffering and, if so, how long that relief might last.
The study involved thirty-seven patients who had undergone chemotherapy and were experiencing moderate to severe nerve pain. These individuals were not new to treatment; their symptoms had been established for months, with some having waited nearly seven months after their chemotherapy ended before seeking help. The researchers used a specialized device that emitted light at three different wavelengths, effectively bathing the affected areas in a spectrum of red and near-infrared energy. The treatment was administered two or three times a week, with each session lasting about eight minutes per area. The patients were treated until they completed a course of therapy, which typically involved around eighteen sessions, though some required more depending on how their symptoms responded.
Before the light therapy began, the patients rated their pain on a scale from zero to ten, with the typical score sitting at a high seven. They also completed a questionnaire designed to measure the specific nature of their nerve symptoms, such as burning sensations or sensitivity to touch. After the treatment courses were finished, the results were striking. The average pain score dropped significantly, falling from seven down to three. Similarly, the score measuring the overall burden of nerve symptoms was cut in half. The researchers noted that this level of improvement was not just a small change; it represented a substantial reduction in the daily suffering these patients endured. Most importantly, this relief was not fleeting. When the researchers checked back with the patients three months after their treatment ended, the vast majority of those who had felt better were still feeling better, suggesting that the light therapy did more than just mask the pain temporarily.
The study also looked closely at who responded to the treatment and who did not, hoping to find a pattern that could predict success. They examined factors such as the patient's age, gender, the type of cancer they had, and the specific chemotherapy drugs they had received. They also considered whether patients had other health issues like diabetes or pre-existing nerve problems. The findings were surprisingly broad: the treatment worked well across the board. It did not matter if the patient had received a common drug like oxaliplatin or a different type of chemotherapy; the relief was consistent. There was no specific group of people who failed to respond, and the treatment appeared safe, with no side effects or complications reported from the light therapy itself. Even in the few cases where patients had to stop treatment early for reasons unrelated to the therapy, the data suggested that the positive trend held up.
One of the most compelling aspects of these findings is the durability of the relief. In a condition where symptoms often linger for years, seeing improvement that lasts for months after the treatment stops is significant. The researchers observed that for the patients who improved, the benefit persisted well beyond the final session. This pattern hints that the light therapy may be encouraging the nerves to heal or repair themselves, rather than just providing a temporary numbing effect. While the study was conducted at a single center and did not include a control group to compare against a placebo, the consistency of the results in a real-world setting of patients with difficult-to-treat symptoms is encouraging. The authors conclude that this light-based approach offers a promising, non-drug option for patients who have few other choices, warranting further investigation in larger, more controlled studies to confirm these early successes.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.